Core Viewpoint - Neuronetics (STIM) shares have increased by 16.1% recently, closing at $5.06, with a potential upside of 35% based on Wall Street analysts' mean price target of $6.83 [1] Price Targets - The average price target consists of three estimates ranging from a low of $5.50 to a high of $8, with a standard deviation of $1.26, indicating variability among analysts [2] - The lowest estimate suggests an 8.7% increase, while the highest indicates a 58.1% upside [2] - A low standard deviation signifies greater agreement among analysts regarding price movement [2][7] Analyst Sentiment - Analysts show increasing optimism about STIM's earnings, with a strong consensus on higher EPS estimates, which correlates with potential stock price increases [4][9] - The Zacks Consensus Estimate for the current year has risen by 58.8% in the past month, with two estimates increasing and no negative revisions [10] Zacks Rank - STIM holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside [11] Conclusion on Price Targets - While consensus price targets may not reliably predict the extent of STIM's gains, they can provide a directional guide for potential price movements [12]

Neuronetics, Inc. (NASDAQ:STIM) Q4 2024 Earnings Conference Call March 4, 2025 8:30 AM ET Company Participants Mark Klausner - Investor Relations Keith Sullivan - President & Chief Executive Officer Steve Furlong - Chief Financial Officer Conference Call Participants William Plovanic - Canaccord Genuity Max Kruszeski - William Blair Adam Maeder - Piper Sandler Danny Stauder - Citizens JMP Operator Good day, and thank you for standing by. Welcome to the Neuronetics Fourth Quarter 2024 Financial and Operating ...

MALVERN, Pa., March 04, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company” or “Neuronetics”) a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the leading neurohealth therapies in the world, today announced its financial and operating results for the fourth quarter and full year of 2024. Fourth Quarter 2024 Highlights Acquired Greenbrook TMS on De ...

Revenue Performance - Preliminary unaudited fourth quarter revenue for 2024 was $22.1 million, and full year revenue was $74.5 million[3]. - Neuronetics' adjusted net pro forma revenue for FY 2024 was $62.0 million after intercompany eliminations[6]. - Neuronetics expects full year 2025 pro forma revenue growth of 12% to 19%, projecting total revenue between $145.0 million and $155.0 million[7][13]. Cost Management - The company anticipates realizing over $22 million in annualized cost synergies, with over 90% already implemented[7][9]. - Operating expenses for FY 2025 are projected to be between $90.0 million and $98.0 million[13]. Strategic Initiatives - The acquisition of Greenbrook TMS was completed on December 9, 2024, enhancing the company's market position in mental health therapy delivery[11]. - The Better Me Provider program launched in July 2024, improving patient care with up to 3 times faster follow-ups and a 2.5x reduction in treatment initiation time[12]. Regulatory and Market Expansion - FDA clearance was received for NeuroStar Advanced Therapy as a first-line treatment for adolescents with major depressive disorder, expanding the total addressable market by approximately 35%[14]. Operational Milestones - Neuronetics achieved cash flow breakeven in the third quarter of 2025[10]. - The company shipped 50 systems in the fourth quarter of 2024[3].

MALVERN, Pa., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced that it plans to release fourth quarter 2024 financial and operating results prior to market open on Tuesday, March 4, 2025. The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day. The conference call wi ...

Core Viewpoint - Neuronetics, Inc. has announced a public offering of 8,000,000 shares of common stock at a price of $2.25 per share, aiming to raise approximately $18 million in gross proceeds before expenses [1][2]. Group 1: Offering Details - The company has granted the underwriter a 30-day option to purchase an additional 1,200,000 shares at the public offering price [2]. - The offering is expected to close on or about February 10, 2025, pending customary closing conditions [2]. - Canaccord Genuity LLC is acting as the sole bookrunner for the offering [3]. Group 2: Use of Proceeds - The net proceeds from the offering will be used for general corporate purposes, including sales and marketing, research and development, potential acquisitions, inventory purchases, and working capital [2]. Group 3: Company Overview - Neuronetics is a leader in neuroscience, focusing on mental health treatments, particularly through its NeuroStar Advanced Therapy, a non-drug, noninvasive treatment for neurohealth conditions [6]. - The company operates Greenbrook TMS Inc. treatment centers across the U.S., providing NeuroStar Therapy for major depressive disorder and other mental health disorders [6][7].

Company Overview - Neuronetics, Inc. is a global leader in neuroscience, focusing on mental health treatments, particularly through its NeuroStar Advanced Therapy, a non-drug, noninvasive treatment for neurohealth conditions [6][7] - The company operates Greenbrook TMS Inc. treatment centers across the United States, providing NeuroStar Therapy for major depressive disorder and other mental health disorders [6] Public Offering Details - Neuronetics has priced its underwritten public offering of 8,000,000 shares of common stock at a price of $2.25 per share, aiming for gross proceeds of approximately $18 million [1][2] - The underwriter has a 30-day option to purchase an additional 1,200,000 shares at the public offering price [2] - The net proceeds from the offering will be used for general corporate purposes, including sales and marketing, research and development, potential acquisitions, and working capital [2] Regulatory and Compliance - A shelf registration statement for the shares was filed with the U.S. Securities and Exchange Commission (SEC) on November 9, 2022, and was declared effective on November 14, 2022 [4] - The offering will be made via a prospectus supplement, with a final prospectus supplement to be filed with the SEC [4] Financial and Market Context - The offering is expected to close on or about February 10, 2025, subject to customary closing conditions [2] - Canaccord Genuity LLC is acting as the sole bookrunner for the offering [3]

Company Overview - Neuronetics, Inc. is a global leader in neuroscience, focusing on mental health treatments, particularly through its NeuroStar Advanced Therapy, a non-drug, noninvasive treatment for neurohealth conditions [5][6] - The company operates Greenbrook TMS Inc. treatment centers across the United States, providing NeuroStar Therapy for major depressive disorder and other mental health disorders [5] Public Offering Announcement - Neuronetics has commenced an underwritten public offering of its common stock, with an expectation to grant the underwriter a 30-day option to purchase up to an additional 15% of the shares offered [1][2] - Canaccord Genuity LLC is acting as the sole bookrunner for this offering, which is subject to market conditions [2] Regulatory and Offering Details - A shelf registration statement for the common stock was filed with the SEC on November 9, 2022, and was declared effective on November 14, 2022 [3] - The offering will be conducted via a prospectus supplement and accompanying prospectus, which will be available on the SEC's website [3] Treatment Indications - NeuroStar Therapy is indicated for treating depressive episodes and reducing anxiety symptoms in adult patients with major depressive disorder who have not responded satisfactorily to previous antidepressant treatments [6] - The therapy is also FDA-cleared as an adjunct treatment for adults with obsessive-compulsive disorder and for adolescents aged 15 to 21 with major depressive disorder [6]

Core Insights - Neuronetics, Inc. has announced two peer-reviewed publications that provide evidence of the effectiveness of transcranial magnetic stimulation (TMS) in improving depressive symptoms and highlight the superior sensitivity of the PHQ-9 assessment tool over the QIDS-SR for measuring TMS outcomes [1][2][5] Group 1: TMS Effectiveness - The first publication demonstrates that TMS induces universal improvement in depressive symptoms across various categories, suggesting a broad antidepressant effect rather than targeting specific symptoms [5][6] - The study involved 578 patients diagnosed with major depressive disorder (MDD) and showed that all three TMS protocols studied were equally effective, allowing for greater flexibility in treatment delivery [6] Group 2: Assessment Tools - The second publication compares the PHQ-9 and QIDS-SR assessment tools, revealing that the PHQ-9 is more sensitive in capturing symptom improvements and identifying higher remission rates than the QIDS-SR [6] - The findings indicate that the QIDS-SR often underreports symptoms and misclassifies patients as "non-responders," while the PHQ-9 provides a more reliable measure of depression severity [6] Group 3: Company Positioning - Neuronetics positions itself as a leader in advancing TMS therapy and mental health treatment, emphasizing its commitment to scientific research and data-driven innovation [2][7] - The company has delivered over 6.9 million NeuroStar Advanced Therapy treatments and operates Greenbrook TMS Inc. treatment centers across the U.S., further solidifying its market presence [8]

Core Insights - Neuronetics, Inc. announced preliminary fourth quarter and full year 2024 revenue, reporting $22.1 million and $74.5 million respectively, reflecting both standalone performance and combined performance with Greenbrook TMS [2][6] - The company expects a pro forma year-over-year revenue growth of 12% to 19% for full year 2025, alongside anticipated annualized cost synergies exceeding $22 million [6][13] - Neuronetics aims to achieve cash flow breakeven by the third quarter of 2025, with reduced cash burn expected in the first half of 2025 [8][6] Financial Performance - Preliminary unaudited revenue for 4Q 2024 was $22.1 million, while full year revenue was $74.5 million [2] - Adjusted gross pro forma revenue for 4Q 2024 was $19.5 million, and for FY 2024 it was $71.9 million [5] - The company reported adjusted net pro forma revenue of $17.1 million for 4Q 2024 and $62.0 million for FY 2024 [5] Acquisition Impact - The acquisition of Greenbrook TMS was completed on December 9, 2024, creating a significant combination in mental health therapy delivery [9] - The integration of Greenbrook's network of over 95 treatment clinics with Neuronetics' NeuroStar technology platform is expected to drive profitable growth and operational cost synergies [9][6] - Over 90% of the identified annual cost synergies of $22 million have already been implemented [7] Business Initiatives - Neuronetics launched the Better Me Provider program in July 2024, enhancing patient care and accessibility, with over 350 active sites and more than 125 additional sites committed to joining [10] - The company received FDA clearance for its NeuroStar Advanced Therapy as a first-line adjunct treatment for adolescents with major depressive disorder, expanding its total addressable market by approximately 35% [11] Future Outlook - For fiscal year 2025, Neuronetics anticipates total revenue between $145 million and $155 million, with a gross margin of approximately 55% [13] - Operating expenses are projected to be between $90 million and $98 million [13]